Clinical Trial Update: A Study to Evaluate D-1553 in Combination Therapy in Non-Small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 study evaluating D-1553 in combination therapy for non-small cell lung cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• D-1553

Snippet

Sponsor: InventisBio Co., Ltd | Conditions: NSCLC | Phase 1, Phase 2 | Status: TERMINATED